These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37921963)

  • 1. Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.
    Costin J; Mouslim MC; Socal MP; Trujillo A
    Pharmacoecon Open; 2024 Jan; 8(1):115-118. PubMed ID: 37921963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
    Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
    JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms.
    Bertuzzi L; Maini L
    Health Aff (Millwood); 2024 May; 43(5):717-724. PubMed ID: 38709961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar strategic implementation at a large health system.
    Kar I; Kronz M; Kolychev E; Silverman P; Mendiratta P; Tomlinson BKN; Prunty J; Copley M; Patel S; Caudill S; Farah L; Wesolowski B; Crissinger T; Kendig C; Szymczak E; Duraj L; Dumot J; Acheson E; Lyamkin S; King M; Mocilnikar A; Cunningham K; Paulic N; Botzki U; Lerman R; Strosaker R; Osborne S; Glotzbecker B
    Am J Health Syst Pharm; 2022 Feb; 79(4):268-275. PubMed ID: 34752608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
    Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
    J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
    Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
    Biologics; 2021; 15():1-15. PubMed ID: 33442230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
    Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of a successful biosimilar adoption program.
    Humphreys SZ
    Future Oncol; 2022 May; 18(16):1997-2006. PubMed ID: 35296160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does competition by health maintenance organizations affect the adoption of cost-containment measures by fee-for-service plans?
    Joesch JM; Wickizer TM; Feldstein PJ
    Am J Manag Care; 1998 Jun; 4(6):832-8. PubMed ID: 10181069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider differences in biosimilar uptake in the filgrastim market.
    Chen AJ; Ribero R; Van Nuys K
    Am J Manag Care; 2020 May; 26(5):208-213. PubMed ID: 32436678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment.
    Chang J; Karaca-Mandic P; Jeffery MM
    Med Care; 2023 Oct; 61(10):636-643. PubMed ID: 37582298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
    Desai RJ; Kim SC; Curtis JR; Bosco JLF; Eichelberger B; Barr CE; Lockhart CM; Bradbury BD; Clewell J; Cohen HP; Gagne JJ;
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):757-769. PubMed ID: 31298463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of Infliximab.
    Feng K; Kesselheim AS; Russo M; Rome BN
    Clin Pharmacol Ther; 2023 Jan; 113(1):90-97. PubMed ID: 36227630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.